The state of Arizona currently has 7 active clinical trials seeking participants for Hereditary Angioedema (HAE) research studies. These trials are conducted in various cities, including Phoenix, Tucson, Scottsdale and Mesa.
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
NCT05392114
Recruiting
The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).
Gender:
All
Ages:
12 years and above
Trial Updated:
06/14/2024
Locations: Ionis Investigative Site, Paradise Valley, Arizona
Conditions: Hereditary Angioedema
Register for Updates
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
NCT05819775
Recruiting
The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.
Gender:
All
Ages:
Between 2 years and 11 years
Trial Updated:
06/03/2024
Locations: Research Solutions of Arizona, Litchfield Park, Arizona +1 locations
Conditions: Hereditary Angioedema (HAE)
Register for Updates
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
NCT06343779
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1 or type 2 (HAE-1/2), a proportion of whom are using long-term prophylactic medication for HAE.
Gender:
All
Ages:
Between 12 years and 75 years
Trial Updated:
04/30/2024
Locations: Study Site, Paradise Valley, Arizona
Conditions: Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency
Register for Updates
A Study of STAR-0215 in Participants With Hereditary Angioedema
NCT05695248
Recruiting
The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of STAR-0215, and two other groups will get 2 doses of STAR-0215. Researchers will study the effects of STAR-0215 in participants with HAE as this is the first time that the drug has been given to participants with HAE.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Medical Research of Arizona a Division of Allergy, Asthma & Immunology Associates, LTD., Scottsdale, Arizona
Conditions: Hereditary Angioedema
Register for Updates
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
NCT05505916
Recruiting
This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.
Gender:
All
Ages:
12 years and above
Trial Updated:
03/06/2024
Locations: KalVista Investigative Site, Scottsdale, Arizona
Conditions: Hereditary Angioedema
Register for Updates
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
NCT05511922
Recruiting
This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
03/06/2024
Locations: KalVista Investigative Site, Scottsdale, Arizona
Conditions: Hereditary Angioedema
Register for Updates
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
NCT05396105
Recruiting
This study evaluates the safety and efficacy of long-term on-demand treatment with orally administered deucrictibant for acute hereditary angioedema (HAE) attacks, including laryngeal attacks, in patients with HAE due to C1-esterase inhibitor (C1-INH) deficiency (type I/II). The study will enroll patients from Study PHA022121-C201 (NCT04618211) who elect to participate in this extension study and meet the eligibility requirements.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2023
Locations: Study site, Scottsdale, Arizona
Conditions: Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency
Register for Updates